GlycoMimetics Inc (GLYC)
0.315
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 11:25
GlycoMimetics Net Income (Quarterly): -9.824M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -9.824M |
| June 30, 2024 | -10.10M |
| March 31, 2024 | -10.74M |
| December 31, 2023 | -9.079M |
| September 30, 2023 | -9.202M |
| June 30, 2023 | -8.259M |
| March 31, 2023 | -10.36M |
| December 31, 2022 | -10.24M |
| September 30, 2022 | -8.524M |
| June 30, 2022 | -13.27M |
| March 31, 2022 | -14.65M |
| December 31, 2021 | -17.42M |
| September 30, 2021 | -17.33M |
| June 30, 2021 | -14.40M |
| March 31, 2021 | -14.27M |
| December 31, 2020 | -15.56M |
| September 30, 2020 | -13.72M |
| June 30, 2020 | -14.08M |
| March 31, 2020 | -7.663M |
| December 31, 2019 | -14.73M |
| September 30, 2019 | -13.25M |
| June 30, 2019 | -15.83M |
| March 31, 2019 | -14.08M |
| December 31, 2018 | -13.91M |
| September 30, 2018 | -11.58M |
| Date | Value |
|---|---|
| June 30, 2018 | -11.28M |
| March 31, 2018 | -11.51M |
| December 31, 2017 | -9.258M |
| September 30, 2017 | -7.950M |
| June 30, 2017 | -8.142M |
| March 31, 2017 | -7.931M |
| December 31, 2016 | -8.329M |
| September 30, 2016 | -7.855M |
| June 30, 2016 | -8.072M |
| March 31, 2016 | -7.555M |
| December 31, 2015 | -8.882M |
| September 30, 2015 | -7.168M |
| June 30, 2015 | 10.39M |
| March 31, 2015 | -7.109M |
| December 31, 2014 | -7.394M |
| September 30, 2014 | -6.618M |
| June 30, 2014 | 7.992M |
| March 31, 2014 | -5.102M |
| December 31, 2013 | -3.867M |
| September 30, 2013 | -3.701M |
| June 30, 2013 | -3.497M |
| March 31, 2013 | 0.4597M |
| December 31, 2012 | 0.638M |
| September 30, 2012 | 0.8226M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-17.42M
Minimum
Dec 2021
-7.663M
Maximum
Mar 2020
-12.17M
Average
-12.00M
Median
Net Income (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 106.08M |
| Arbutus Biopharma Corp | -19.72M |
| Revance Therapeutics Inc | -38.12M |
| FibroGen Inc | -17.08M |
| Cidara Therapeutics Inc | -15.98M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.721M |
| EPS Diluted (Quarterly) | -0.15 |
| Enterprise Value | 6.243M |
| Earnings Yield | -196.8% |
| Normalized Earnings Yield | -184.13 |